Loading…
Lakewood-Amedex Biotherapeutics, Inc. is projected to rise to $3.66 by 2027, a +40% move from its current price of $2.61. LABT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.37 | $2.61 | $2.88 | +0.07% |
| Jul 14 | $2.28 | $2.61 | $3.00 | +0.13% |
| Jul 15 | $2.21 | $2.62 | $3.10 | +0.20% |
| Jul 16 | $2.15 | $2.62 | $3.18 | +0.26% |
| Jul 17 | $2.10 | $2.62 | $3.26 | +0.33% |
| Jul 18 | $2.06 | $2.62 | $3.33 | +0.39% |
| Jul 19 | $2.02 | $2.62 | $3.40 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.02 | $2.62 | $3.40 | +0.46% |
| Week 2 | $1.83 | $2.63 | $3.80 | +0.92% |
| Week 3 | $1.69 | $2.65 | $4.14 | +1.38% |
| Week 4 | $1.59 | $2.66 | $4.46 | +1.85% |
| Week 5 | $1.50 | $2.67 | $4.76 | +2.31% |
| Week 6 | $1.42 | $2.68 | $5.05 | +2.78% |
| Week 7 | $1.36 | $2.69 | $5.34 | +3.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs.
It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc.
in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
LABT is the ticker for Lakewood-Amedex Biotherapeutics, Inc. The current price is $2.64 and the market capitalization is $4.62M, with the stock ranked 5354. The near-term technical context shows a 30-day price range from $1.36 to $5.11, with a support level at $2.38 and a resistance at $7.70.
The forecast confirms a path from a neutral start in 2026 toward higher levels later, with multiple years showing upside potential through 2050, including increases in average price and ROI in several years.
A major floor 85.1% below — a decisive break under it would weaken the trend.
The nearest floor, 8.8% below — buyers have tended to step in here.
The nearest ceiling, 195.0% above — a clean break opens room to run.
A major ceiling 231.4% above — clearing it would confirm fresh momentum.
Key LABT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LABT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.55 | Buy | $2.63 | Sell |
| MA 10 | $2.89 | Sell | $2.67 | Sell |
| MA 20 | $2.38 | Buy | $2.47 | Buy |
| MA 50 | $1.97 | Buy | $2.92 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.19 | Neutral |
| Stoch RSI (14) | 14.32 | Buy |
| CCI (20) | 14.62 | Neutral |
| Williams %R (14) | -85.53 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -34.26 | Sell |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 14.47 | Buy |
| TRIX (15) | 2.01 | Buy |
| Awesome (5,34) | 0.87 | Buy |
| Ultimate (7,14,28) | 46.35 | Neutral |
| Momentum (10) | -0.82 | Sell |
| Aroon Osc (25) | 8.00 | Buy |
| Hull MA (9) | 2.35 | Buy |
| ADX (14) | 32.94 | Buy |
| ATR (14) | 0.27 | Info |
The near-term technical picture remains NEUTRAL. RSI14 is 20, signaling oversold conditions by some measures while momentum has not shifted decisively. The stock trades with a 50-day simple moving average of $12.51, and price action touches a support at $2.38 and faces resistance at $7.70.
Over the last 30 days, the price has traded within a range of $1.36 to $5.11.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.38 | $2.61 | $4.89 | 0% | Neutral | |
| $2.39 | $3.66 | $6.06 | +40% | Bullish | |
| $2.38 | $4.04 | $7.29 | +55% | Bullish | |
| $1.89 | $3.52 | $6.77 | +35% | Bullish | |
| $1.47 | $2.99 | $6.05 | +15% | Neutral | |
| $1.56 | $3.46 | $7.31 | +33% | Bullish | |
| $1.45 | $3.22 | $7.07 | +23% | Bullish | |
| $1.82 | $4.05 | $9.22 | +55% | Bullish | |
| $2.34 | $5.19 | $11.94 | +99% | Bullish | |
| $2.13 | $4.74 | $10.90 | +82% | Bullish | |
| $2.83 | $6.29 | $14.47 | +141% | Bullish | |
| $3.91 | $8.68 | $19.97 | +233% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.38 | $2.61 | $3.45 | +0.00% |
| August 2026 | $2.32 | $2.88 | $3.78 | +10.43% |
| September 2026 | $2.18 | $2.77 | $3.74 | -3.89% |
| October 2026 | $2.21 | $2.87 | $3.97 | +3.48% |
| November 2026 | $2.46 | $3.24 | $4.58 | +12.91% |
| December 2026 | $2.54 | $3.40 | $4.89 | +4.92% |
Click any year to see its month-by-month LABT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LABT is projected to trade between $2.38 and $4.89, averaging $2.61 — a potential gain of 0% from today's $2.61. Price action looks broadly range-bound.
Lakewood-Amedex Biotherapeutics, Inc.'s 2027 outlook centres on $3.66, within a $2.39 to $6.06 range. That is up +40% on the projected 2026 average. That marks a +40% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, LABT could reach as high as $7.29, with a base case around $4.04 and support toward $2.38 — roughly +55% from $2.61. Momentum favours further upside here.
Expect LABT to range from $1.89 to $6.77 through 2029. The $3.52 average target implies a +35% move from current prices. That is -13% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The LABT price prediction for 2030 points to an average of $2.99 (low $1.47, high $6.05) — a potential gain of +15% on today's $2.61. Price action looks broadly range-bound.
In 2031, LABT is projected to trade between $1.56 and $7.31, averaging $3.46 — a potential gain of +33% from today's $2.61. That is up +16% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Lakewood-Amedex Biotherapeutics, Inc.'s 2032 outlook centres on $3.22, within a $1.45 to $7.07 range. That is -7% versus the projected 2031 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2033, LABT could reach as high as $9.22, with a base case around $4.05 and support toward $1.82 — roughly +55% from $2.61. Buyers look set to stay in control over this stretch.
Expect LABT to range from $2.34 to $11.94 through 2034. The $5.19 average target implies a +99% move from current prices. That is up +28% on the projected 2033 average. Momentum favours further upside here.
The LABT price prediction for 2035 points to an average of $4.74 (low $2.13, high $10.90) — a potential gain of +82% on today's $2.61. Buyers look set to stay in control over this stretch.
In 2040, LABT is projected to trade between $2.83 and $14.47, averaging $6.29 — a potential gain of +141% from today's $2.61. That is up +33% on the projected 2035 average. Momentum favours further upside here.
Lakewood-Amedex Biotherapeutics, Inc.'s 2050 outlook centres on $8.68, within a $3.91 to $19.97 range. That is up +38% on the projected 2040 average. That marks a +233% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in LABT today (≈ 383.141762 LABT) could be worth
$3,326.02
+$2,326.02 (+233%) by 2050 · US Dollar
Based on the average projected LABT price of $8.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LABTwould be worth at today's price.
$1,000 invested in LABT on Apr 23, 2026 (≈ 115.606942 LABT) would be worth
$301.73
-$698.27 (-69.8%) today · 0.30× · US Dollar
Based on a LABT entry price of $8.65 vs. today's $2.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.75 | $949.09 | -5.1% |
| 1 month ago | $0.76 | $3,434.21 | +243.4% |
| All time ago | $8.65 | $301.73 | -69.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LABT forecast.
Our base-case forecast reaches $5.20 around 2040.
Implied market cap at $5.20: $9.1M
The multi-year forecast maps out a path from 2026 through 2050. In 2026 the min is $2.38, the avg is $2.64, the max is $4.95, with ROI 0 and sentiment NEUTRAL. In 2027 the min is $2.42, the avg is $3.70, the max is $6.14, with ROI 40.3 and sentiment BULLISH.
In 2028 the min is $2.41, the avg is $4.09, the max is $7.38, with ROI 55.1 and sentiment BULLISH. In 2029 the min is $1.91, the avg is $3.55, the max is $6.82, with ROI 34.5 and sentiment BULLISH. In 2030 the min is $1.49, the avg is $3.03, the max is $6.13, with ROI 14.7 and sentiment NEUTRAL.
In 2031 the min is $1.59, the avg is $3.51, the max is $7.43, with ROI 33 and sentiment BULLISH. In 2032 the min is $1.46, the avg is $3.24, the max is $7.12, with ROI 22.7 and sentiment BULLISH. In 2033 the min is $1.85, the avg is $4.10, the max is $9.34, with ROI 55.4 and sentiment BULLISH.
In 2034 the min is $2.37, the avg is $5.28, the max is $12.13, with ROI 99.8 and sentiment BULLISH. In 2035 the min is $2.15, the avg is $4.77, the max is $10.98, with ROI 80.8 and sentiment BULLISH. In 2040 the min is $2.87, the avg is $6.38, the max is $14.68, with ROI 141.7 and sentiment BULLISH.
In 2050 the min is $3.94, the avg is $8.76, the max is $20.14, with ROI 231.7 and sentiment BULLISH. These figures illustrate potential upside across the forecast horizon, but they are estimates and not guarantees, and actual results may differ given market and clinical development dynamics.
Tap a question to reveal the answer.
In 2030, the forecast provides a min of $1.49, an avg of $3.03, and a max of $6.13, for an expected ROI of 14.7, with sentiment NEUTRAL.
The forecast shows multiple bullish years, including 2027, 2028, 2033, 2034, 2035, 2040 and 2050, with positive ROI values in those years, while 2026 is neutral. These are estimates and not guarantees.
Yes. The forecast's max by year shows $12.13 in 2034.
Current price is $2.64 and market capitalization is $4.62M.
The 30-day range is from $1.36 to $5.11.
Lakewood-Amedex Biotherapeutics, Inc. Community Discussion
0Share your Lakewood-Amedex Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.